Cargando…

Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin

BACKGROUND: As new interventions to reduce childhood mortality are identified, careful consideration must be given to identifying populations that could benefit most from them. Promising reductions in childhood mortality reported in a large cluster randomized trial of mass drug administration (MDA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Matheson, Alastair I., Manhart, Lisa E., Pavlinac, Patricia B., Means, Arianna R., Akullian, Adam, Levine, Gillian A., Jacobson, Julie, Shutes, Erin, Walson, Judd L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023929/
https://www.ncbi.nlm.nih.gov/pubmed/24837459
http://dx.doi.org/10.1371/journal.pone.0096658
_version_ 1782316588767117312
author Matheson, Alastair I.
Manhart, Lisa E.
Pavlinac, Patricia B.
Means, Arianna R.
Akullian, Adam
Levine, Gillian A.
Jacobson, Julie
Shutes, Erin
Walson, Judd L.
author_facet Matheson, Alastair I.
Manhart, Lisa E.
Pavlinac, Patricia B.
Means, Arianna R.
Akullian, Adam
Levine, Gillian A.
Jacobson, Julie
Shutes, Erin
Walson, Judd L.
author_sort Matheson, Alastair I.
collection PubMed
description BACKGROUND: As new interventions to reduce childhood mortality are identified, careful consideration must be given to identifying populations that could benefit most from them. Promising reductions in childhood mortality reported in a large cluster randomized trial of mass drug administration (MDA) of azithromycin (AZM) prompted the development of visually compelling, easy-to-use tools that synthesize country-specific data on factors that would influence both potential AZM benefit and MDA implementation success. METHODOLOGY/PRINCIPAL FINDINGS: We assessed the opportunity to reduce mortality and the feasibility of implementing such a program, creating Opportunity and Feasibility Indices, respectively. Countries with high childhood mortality were included. A Country Ranking Index combined key variables from the previous two Indices and applied a scoring system to identify high-priority countries. We compared four scenarios with varying weights given to each variable. Twenty-five countries met inclusion criteria. We created easily visualized tools to display the results of the Opportunity and Feasibility Indices. The Opportunity Index revealed substantial variation in the opportunity for an MDA of AZM program to reduce mortality, even among countries with high overall childhood mortality. The Feasibility Index demonstrated that implementing such a program would be most challenging in the countries that could see greatest benefit. Based on the Country Ranking Index, Equatorial Guinea would benefit the most from the MZA of AZM in three of the four scenarios we tested. CONCLUSIONS/SIGNIFICANCE: These visually accessible tools can be adapted or refined to include other metrics deemed important by stakeholders, and provide a quantitative approach to prioritization for intervention implementation. The need to explicitly state metrics and their weighting encourages thoughtful and transparent decision making. The objective and data-driven approach promoted by the three Indices may foster more efficient use of resources.
format Online
Article
Text
id pubmed-4023929
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40239292014-05-21 Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin Matheson, Alastair I. Manhart, Lisa E. Pavlinac, Patricia B. Means, Arianna R. Akullian, Adam Levine, Gillian A. Jacobson, Julie Shutes, Erin Walson, Judd L. PLoS One Research Article BACKGROUND: As new interventions to reduce childhood mortality are identified, careful consideration must be given to identifying populations that could benefit most from them. Promising reductions in childhood mortality reported in a large cluster randomized trial of mass drug administration (MDA) of azithromycin (AZM) prompted the development of visually compelling, easy-to-use tools that synthesize country-specific data on factors that would influence both potential AZM benefit and MDA implementation success. METHODOLOGY/PRINCIPAL FINDINGS: We assessed the opportunity to reduce mortality and the feasibility of implementing such a program, creating Opportunity and Feasibility Indices, respectively. Countries with high childhood mortality were included. A Country Ranking Index combined key variables from the previous two Indices and applied a scoring system to identify high-priority countries. We compared four scenarios with varying weights given to each variable. Twenty-five countries met inclusion criteria. We created easily visualized tools to display the results of the Opportunity and Feasibility Indices. The Opportunity Index revealed substantial variation in the opportunity for an MDA of AZM program to reduce mortality, even among countries with high overall childhood mortality. The Feasibility Index demonstrated that implementing such a program would be most challenging in the countries that could see greatest benefit. Based on the Country Ranking Index, Equatorial Guinea would benefit the most from the MZA of AZM in three of the four scenarios we tested. CONCLUSIONS/SIGNIFICANCE: These visually accessible tools can be adapted or refined to include other metrics deemed important by stakeholders, and provide a quantitative approach to prioritization for intervention implementation. The need to explicitly state metrics and their weighting encourages thoughtful and transparent decision making. The objective and data-driven approach promoted by the three Indices may foster more efficient use of resources. Public Library of Science 2014-05-16 /pmc/articles/PMC4023929/ /pubmed/24837459 http://dx.doi.org/10.1371/journal.pone.0096658 Text en © 2014 Matheson et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Matheson, Alastair I.
Manhart, Lisa E.
Pavlinac, Patricia B.
Means, Arianna R.
Akullian, Adam
Levine, Gillian A.
Jacobson, Julie
Shutes, Erin
Walson, Judd L.
Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title_full Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title_fullStr Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title_full_unstemmed Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title_short Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin
title_sort prioritizing countries for interventions to reduce child mortality: tools for maximizing the impact of mass drug administration of azithromycin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023929/
https://www.ncbi.nlm.nih.gov/pubmed/24837459
http://dx.doi.org/10.1371/journal.pone.0096658
work_keys_str_mv AT mathesonalastairi prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT manhartlisae prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT pavlinacpatriciab prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT meansariannar prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT akullianadam prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT levinegilliana prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT jacobsonjulie prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT shuteserin prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin
AT walsonjuddl prioritizingcountriesforinterventionstoreducechildmortalitytoolsformaximizingtheimpactofmassdrugadministrationofazithromycin